Table 4.

Twenty-four patients who had PIK3CA mutations before neoadjuvant chemotherapy and changes in the PIK3CA mutations after neoadjuvant chemotherapy

IDPIK3CA status before NCTPIK3CA status after NCTTumor cell percentage after NCT (%)Tumor typeER statusPR statusHER2 statusRegimensPathologic response
139H1047RWT50IDC++TPNon-pCR
185H1047RWT70IDC+ANon-pCR
544H1047RWT10IDC++A-TPNon-pCR
557Q815RWT50IDC+A-TPNon-pCR
717E545KWT0ILC+A-TPpCR
779E1064fsWT0IDC++TPpCR
990H1047RWT30IDCA-TNon-pCR
1057H1047RWT20IDC++ANon-pCR
1416E545KWT0IDC+TpCR
710N345KN345K70IDC++A-TPNon-pCR
915E545KE545K60IDC++TNon-pCR
1015E545KE545K40IDC++A-TNon-pCR
1132E545KE545K70IDC++ANon-pCR
360E542KE542K20IDC++ANon-pCR
1556E542KE542K40IDC++TNon-pCR
306H1047R, Q815RH1047R, Q815R60IDC++A-TPNon-pCR
505H1047RH1047R30IDC+++A-TPNon-pCR
653H1047RH1047R50IDC++A-TPNon-pCR
663H1047RH1047R70IDC++A-TPNon-pCR
989H1047RH1047R50IDC++A-TNon-pCR
994H1047RH1047R50IDC+ANon-pCR
467H1047LH1047L80IDCA-TNon-pCR
878H1047LH1047L40IDC++A-TNon-pCR
1541H1047LH1047L30IDC++ANon-pCR

Abbreviations: NCT, neoadjuvant chemotherapy; IDC, invasive ductal carcinoma; ILC, invasive lobular carcinoma; A, anthracycline; T, taxane; TP, taxane plus carboplatin.